Poolbeg Pharma PLC (POLB.L)

13.90 +0.25 (+1.83%) At close: 04:06PM BST

Poolbeg Pharma PLC

Queen Mary BioEnterprises Innovation Centre
42 New Road
London E1 2AX
United Kingdom
44 20 7183 1499
https://www.poolbegpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 15

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Cathal Martin Friel	Executive Chairman of The Board	150k	N/A	1964
Dr. Jeremy Skillington Ph.D.	CEO & Director	362k	N/A	1971
Mr. Ian O'Connell	CFO & Director	237k	N/A	1987
Carol Dalton	Vice President of Investor Relations & Public Relations	N/A	N/A	N/A
Mr. John McEvoy	Senior Vice President & Chief Legal Officer	N/A	N/A	N/A
Mr. David James Allmond	Chief Business Officer	N/A	N/A	1970
Mr. Ross Crockett	Group Financial Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Corporate governance

Poolbeg Pharma PLC’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.